NICE rejects Erbitux in colorectal cancer
This article was originally published in Scrip
Draft guidance from the National Institute for health and Clinical Excellencedoes not recommendMerck Serono's Erbitux (cetuximab) for the first-line treatment of metastatic colorectal cancer (mCRC), suggesting that national health service patients in England and Wales will not have access to the drug. NICE has already rejected Erbitux in the second and third-line treatment of mCRC and limited its use in locally advanced squamous cell cancer of the head and neck to a small subset of patients (Scrip Online, January 24th, 2007 and February 15th, 2008).
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.